Cypherpunk Technologies posted a Q3 2025 net loss of $3.3 million, substantially narrower than the $18.2 million loss in Q3 2024, reflecting a major reduction in research and development expenses following a corporate restructuring and trial completions.

Leap Therapeutics reported a net loss of $16.6 million for Q2 2025, an improvement from the prior year, driven by lower R&D and G&A expenses. Operating expenses were reduced through strategic workforce reductions, and the company is actively exploring strategic alternatives for its clinical assets.

Leap Therapeutics experienced a net loss of $15.435 million in the first quarter of 2025, an increase from the $13.820 million net loss in the same period last year. This was primarily driven by higher research and development expenses, particularly in the DKN-01 program, and a significant decrease in interest income. The company also announced a strategic restructuring to prioritize clinical development and reduce its workforce.

The company reported no revenue for Q4 2024 and recorded higher research and development expenses year-over-year, contributing to a net loss of $15.4 million for the quarter. Leap continued advancing its clinical programs, with positive data from the DeFianCe study supporting future registrational trials.

Leap Therapeutics reported a net loss of $18.2 million for the third quarter of 2024, compared to a net loss of $13.7 million for the same period in 2023. Research and development expenses increased to $14.9 million, and the company's cash and cash equivalents totaled $62.8 million as of September 30, 2024.

Leap Therapeutics reported a net loss of $20.4 million for the second quarter of 2024, compared to a net loss of $13.4 million for the same period in 2023. Research and development expenses increased to $17.9 million, driven by higher clinical trial costs. Cash and cash equivalents totaled $78.5 million at the end of the quarter.

Leap Therapeutics reported a net loss of $13.8 million for the first quarter of 2024. The company's cash and cash equivalents totaled $54.9 million at the end of the quarter, exclusive of the $37.2 million net proceeds from a private placement completed in April 2024. A recent $40 million financing extends the cash runway into the second quarter of 2026.

Leap Therapeutics reported its Q4 2023 financial results, highlighting advancements in DKN-01 and the integration of its pipeline. Enrollment is complete in Part C of the DisTinGuish study, with data expected mid-year.

Leap Therapeutics reported a net loss of $13.7 million for the third quarter of 2023, compared to a net loss of $15.1 million for the same period in 2022. The decrease in net loss was primarily due to decreased research and development expenses and increased interest income. Cash and cash equivalents totaled $80.7 million at September 30, 2023.

Leap Therapeutics reported a net loss of $13.4 million for the second quarter of 2023, compared to $17.0 million for the same period in 2022. The decrease was primarily due to decreased research and development expenses and increased interest income. Cash and cash equivalents totaled $91.4 million at June 30, 2023.

Leap Therapeutics reported a net loss of $41.9 million for the first quarter of 2023, primarily due to in-process research & development (IPR&D) expense associated with the acquisition of Flame Biosciences. They are in a strong financial position to develop their pipeline of personalized medicines for cancer patients.

Leap Therapeutics reported its Q4 2022 financial results, highlighting the advancement of DKN-01 into a randomized controlled clinical trial for gastric cancer and the acquisition of Flame Biosciences, which included FL-301 and approximately $50 million in cash.

Leap Therapeutics reported a net loss of $15.1 million for the third quarter of 2022. The company is focused on advancing its DKN-01 program and has initiated Part C of the DisTinGuish gastric cancer study and the DeFianCe colorectal cancer trial.

Leap Therapeutics reported a net loss of $17.0 million for the second quarter of 2022, compared to a net loss of $9.5 million for the same period in 2021. Research and development expenses were $14.0 million, compared to $7.2 million for the three months ended June 30, 2021. Cash and cash equivalents totaled $90.9 million at June 30, 2022.

Leap Therapeutics reported a net loss of $10.4 million for the first quarter of 2022. There were no license revenues recognized in the first quarter 2022, as the upfront payment was fully recognized as of December 31, 2021. Cash and cash equivalents totaled $103.2 million at March 31, 2022.

Leap Therapeutics reported Q4 2021 financial results, highlighting DKN-01 development and a strategic collaboration with BeiGene. License revenues were $0.4 million. Research and development expenses were $8.1 million, and general and administrative expenses were $2.8 million. Cash and cash equivalents totaled $114.9 million at the end of the year.

Leap Therapeutics reported a net loss of $11.1 million for the third quarter of 2021, with license revenues of $0.4 million. Research and development expenses increased to $10.1 million, and cash and cash equivalents totaled $124.8 million at the end of the quarter.

Leap Therapeutics reported a net loss of $9.5 million for the second quarter of 2021. The company made significant clinical progress in the DisTinGuish study of DKN-01 in combination with BeiGene’s tislelizumab, completing enrollment in the first-line patient cohort.

Leap Therapeutics reported a net loss of $9.1 million for the first quarter of 2021, compared to a net loss of $7.2 million for the same period in 2020. License revenues were $0.4 million for both the first quarter of 2021 and 2020.

Leap Therapeutics reported its Q4 and full year 2020 financial results, highlighting a transformative year marked by a strategic alliance with BeiGene and the advancement of the DKN-01 development program.

Leap Therapeutics reported a net loss of $7.1 million for the third quarter of 2020, compared to a net loss of $7.9 million for the same period in 2019. The decrease in net loss was primarily due to revenue recognized from the BeiGene agreement, a decrease in clinical development expenses, and non-cash foreign currency gains.

Leap Therapeutics reported a net loss of $6.5 million for the second quarter of 2020, compared to $8.4 million for the same period in 2019. The company's cash, cash equivalents, and marketable securities totaled $64.9 million at June 30, 2020.

Leap Therapeutics reported a net loss of $7.2 million for Q1 2020, a decrease compared to $8.6 million for the same period in 2019. The decrease was primarily due to revenue recognized from the BeiGene agreement and a decrease in clinical development expenses.

Leap Therapeutics reported its Q4 2019 financial results, noting a decrease in research and development expenses due to reduced clinical trial costs and lower manufacturing and consulting expenses. The company highlighted progress in the clinical development of DKN-01 and securing a strategic partnership with BeiGene.